OBJECTIVES/HYPOTHESIS: The human papillomavirus (HPV) has been identified as a causative factor in 20% to 25% of all head and neck squamous cell carcinomas (HNSCC). Ongoing research suggests that the presence of HPV DNA in HNSCC predicts a positive prognosis with respect to disease-free and overall survival. However, most studies have been limited by the heterogeneity in treatment regimens and/or anatomic subsites of tumor origin. In this study, we correlate clinical outcomes with HPV status for patients with oropharyngeal carcinomas who were uniformly treated with a concurrent chemoradiation treatment protocol. STUDY DESIGN: Retrospective study. METHODS: Demographic and clinicopathologic parameters, including age at diagnosis, gender, race, smoking and alcohol history, tumor stage and grade, locoregional recurrence, metastatic spread, recurrence-free survival, overall survival and disease-specific death, were obtained from medical charts and established databases. These parameters were correlated with HPV status of the tumors established by in situ hybridization analysis. RESULTS: HPV positivity correlated with improved clinical outcomes regarding locoregional control (P = .042), recurrence-free survival (P = .009), overall survival (P = .017), and disease-specific death (P = .09). Advanced T stage was a significant risk factor for recurrence and death independent of HPV status. CONCLUSIONS: In patients with oropharyngeal carcinoma uniformly treated with chemoradiation, the presence of HPV is a favorable prognostic indicator with respect to recurrence and overall survival. However, advanced T stage was an independent risk factor for recurrence and death that can to some degree offset this benefit.
OBJECTIVES/HYPOTHESIS: The human papillomavirus (HPV) has been identified as a causative factor in 20% to 25% of all head and neck squamous cell carcinomas (HNSCC). Ongoing research suggests that the presence of HPV DNA in HNSCC predicts a positive prognosis with respect to disease-free and overall survival. However, most studies have been limited by the heterogeneity in treatment regimens and/or anatomic subsites of tumor origin. In this study, we correlate clinical outcomes with HPV status for patients with oropharyngeal carcinomas who were uniformly treated with a concurrent chemoradiation treatment protocol. STUDY DESIGN: Retrospective study. METHODS: Demographic and clinicopathologic parameters, including age at diagnosis, gender, race, smoking and alcohol history, tumor stage and grade, locoregional recurrence, metastatic spread, recurrence-free survival, overall survival and disease-specific death, were obtained from medical charts and established databases. These parameters were correlated with HPV status of the tumors established by in situ hybridization analysis. RESULTS:HPV positivity correlated with improved clinical outcomes regarding locoregional control (P = .042), recurrence-free survival (P = .009), overall survival (P = .017), and disease-specific death (P = .09). Advanced T stage was a significant risk factor for recurrence and death independent of HPV status. CONCLUSIONS: In patients with oropharyngeal carcinoma uniformly treated with chemoradiation, the presence of HPV is a favorable prognostic indicator with respect to recurrence and overall survival. However, advanced T stage was an independent risk factor for recurrence and death that can to some degree offset this benefit.
Authors: Claudia Lill; Gabriela Kornek; Barbara Bachtiary; Edgar Selzer; Christian Schopper; Martina Mittlboeck; Martin Burian; Friedrich Wrba; Dietmar Thurnher Journal: Wien Klin Wochenschr Date: 2011-03-30 Impact factor: 1.704
Authors: Benjamin H Lok; Jeremy Setton; Nicola Caria; Jonathan Romanyshyn; Suzanne L Wolden; Michael J Zelefsky; Jeffery Park; Nicholas Rowan; Eric J Sherman; Matthew G Fury; Alan Ho; David G Pfister; Richard J Wong; Jatin P Shah; Dennis H Kraus; Zhigang Zhang; Karen D Schupak; Daphna Y Gelblum; Shyam D Rao; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: A M Hong; T A Dobbins; C S Lee; D Jones; G B Harnett; B K Armstrong; J R Clark; C G Milross; J Kim; C J O'Brien; B R Rose Journal: Br J Cancer Date: 2010-10-19 Impact factor: 7.640
Authors: Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: K Kelly Gallagher; Sagar Deshpande; Catherine N Tchanque-Fossuo; Alexis Donneys; Deniz Sarhaddi; Noah S Nelson; Douglas B Chepeha; Steven R Buchman Journal: Head Neck Date: 2013-01-17 Impact factor: 3.147
Authors: Brian M Lin; Hao Wang; Gypsyamber D'Souza; Zhe Zhang; Carole Fakhry; Andrew W Joseph; Virginia E Drake; Giuseppe Sanguineti; William H Westra; Sara I Pai Journal: Cancer Date: 2013-07-16 Impact factor: 6.860